Singapore-based Lion TCR Pte Ltd, a clinical-stage biotech company specialized in the development and commercialisation of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognised as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organised by IMAPAC.